The latter enrolled 190 patients with obesity (mean age 54.4 years, mean BMI 36.1 kg/m 2 ) and biopsy-proven MASH and moderate-to-severe fibrosis regardless of the presence of T2D, showing a BW reduction of 10.7%, 13.3%, 15.6% and 0.8% at 52 weeks with tirzepatide 5 mg, 10 mg, 15 mg and placebo, respectively 39
They are quick, safe, and can be tailored to your needs
If endometriotic lesions rely on aberrant metabolism for survival, medications that correct metabolic dysfunction could theoretically undermine the metabolic support those lesions depend on
Multivariable logistic regression analyses and thematic synthesis were undertaken
BPC 157's potential collagen-boosting and inflammation-managing effects make it an enticing option for addressing these types of concerns